Clinical Research Directory
Browse clinical research sites, groups, and studies.
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)
Sponsor: Nanjing Medical University
Summary
This is a multi-center, randomized controlled study to investigate whether early offering PCSK9 inhibitor can protect against negative inflammatory response and organ dysfunction after coronary artery bypass grafting (CABG). Subjects with myocardial ischaemic syndromes (MIS) will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy, while the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later. Six month after CABG, CRP will be used to evaluate inflammation, and echocardiography and coronary CTA will be used to evaluate cardiovascular function.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2025-01-01
Completion Date
2026-12-31
Last Updated
2024-12-12
Healthy Volunteers
No
Interventions
PCSK9 inhibitor
the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
Statin
the control group will receive standard statin therapy.
Locations (2)
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China